Drug Interactions between Biktarvy and maribavir
This report displays the potential drug interactions for the following 2 drugs:
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- maribavir
Interactions between your drugs
bictegravir maribavir
Applies to: Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) and maribavir
MONITOR: Coadministration with maribavir may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to maribavir-mediated inhibition of the BCRP transport protein. There are no clinical data regarding the use of maribavir with BCRP substrates.
MANAGEMENT: Caution is advised when maribavir is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring as well as dosage adjustments may be appropriate for some drugs whenever maribavir is added to or withdrawn from therapy.
References
- (2021) "Product Information. Livtencity (maribavir)." Takeda Pharmaceuticals America
Drug and food interactions
tenofovir food
Applies to: Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.
References
- (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.